New Study Casts Doubt on Intranasal Ketamine Sprays for Depression

by Colleen Fleiss on  March 17, 2018 at 10:45 PM Mental Health News
RSS Email Print This Page Comment bookmark
Font : A-A+

Nasal spray devices have been touted as a promising way to deliver ketamine to patients with depression. Latest study reveals the unpredictable nature of intranasal ketamine tolerance from one person to the next. The results are published today in Journal of Psychopharmacology.
New Study Casts Doubt on Intranasal Ketamine Sprays for Depression
New Study Casts Doubt on Intranasal Ketamine Sprays for Depression

Yet contrary to previous trials, this "It's clear that the intranasal method of ketamine delivery is not as simple as it first seemed," said lead author UNSW Professor Colleen Loo, who is based at Black Dog Institute.

Show Full Article


"Many factors are at play when it comes to nasal spray ketamine treatments. Absorption will vary between people and can fluctuate on any given day within an individual based on such things as mucous levels in the nose and the specific application technique used."

The pilot trial aimed to test the feasibility of repeated doses of ketamine through an intranasal device amongst 10 participants with severe depression, ahead of a larger randomised controlled trial.

Participants were first given extensive training in proper self-administration techniques before receiving either a course of eight ketamine treatments or an active control over a period of four weeks, under supervision at the study centre.

Following initial reactions to the nasal spray, the dosage was adjusted amongst study patients to include longer time intervals between sprays.

However, the pilot study was eventually suspended after testing with five participants due to unexpected problems with tolerability. Side effects included high blood pressure, psychotic-like effects and motor incoordination which left some participants unable to continue to self-administer the spray.

"Intranasal ketamine delivery is very potent as it bypasses metabolic pathways, and ketamine is rapidly absorbed into the bloodstream," said Professor Loo.

""Other recent studies have questioned whether changes to ketamine's composition after being metabolised into derivative compounds may actually deliver useful therapeutic effects.

"It remains unclear whether ketamine nasal sprays can be safely relied upon as a treatment for patients with severe depression."

An earlier world-first study led by Professor Loo last year showed the effectiveness of ketamine's antidepressant effects in elderly patients when delivered in repeated doses, which were adjusted on an individual basis and given by the subcutaneous method (injections under the skin).

"Our prior research has shown that altering the dose on an individual patient basis was important. However, we wanted to see if a simpler approach using a set dose of ketamine for all people and administered by nasal spray could work just as well in this latest pilot," said Professor Loo.

"More research is needed to identify the optimal level of ketamine dosage for each specific application method before nasal sprays can be considered a feasible treatment option."

Her team is now recruiting participants for the world's largest independent trial of ketamine to treat depression, to determine the safety and effects of repeated dosing using subcutaneous injections.

Source: Eurekalert

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

Recommended Reading

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive